The stock of Aclaris Therapeutics Incorporated (NASDAQ:ACRS) registered an increase of 12.68% in short interest. ACRS’s total short interest was 622,200 shares in September as published by FINRA. Its up 12.68% from 552,200 shares, reported previously. With 61,000 shares average volume, it will take short sellers 10 days to cover their ACRS’s short positions. The short interest to Aclaris Therapeutics Incorporated’s float is 6.27%. About 44,992 shares traded hands. Aclaris Therapeutics Inc (NASDAQ:ACRS) has risen 13.59% since February 8, 2016 and is uptrending. It has underperformed by 2.90% the S&P500.
Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company. The company has a market cap of $523.40 million. The Firm is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. It currently has negative earnings. The Company’s lead drug candidate, A-101 Topical Solution, is a high-concentration hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis , a non-malignant skin tumor.
Out of 3 analysts covering Aclaris Therapeutics (NASDAQ:ACRS), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Aclaris Therapeutics has been the topic of 6 analyst reports since November 2, 2015 according to StockzIntelligence Inc. Jefferies maintained the stock on August 12 with “Buy” rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.